Depressive Episode Clinical Trial
— MINDDEOfficial title:
Characterisation of Fundamental Decision Making in People Suffering From a Characterised Depressive Episode
The investigators will include patients suffering from Major Depressive Disorder (MDD), in episode. The patients will undertake neuropsychological tasks evaluating executive function and clinical assessment related to depressive symptoms, anxiety, transdiagnostic symptoms and psychological skills.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | August 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age between 18 and 65 years. - Diagnosis of a depressive episode according to DSM-5 criteria, confirmed by the Mini International Neuropsychiatric Interview (MINI 7.0 according to DSM-5). - No evidence of bipolar disorder or schizophrenia, confirmed by the MINI. - No dementing neurological disease. - No guardianship or trusteeship Exclusion Criteria: - Opposition to data processing - Depressive episode in the context of a known bipolar disorder or schizophrenic illness |
Country | Name | City | State |
---|---|---|---|
France | Clinique psychiatrique universitaire | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MADRS score | The severity of the depression will be assessed using the MADRS score. Montgomery-Asberg Depression Scale (MADRS) The scale has 10 items rated from 0 to 6.
0 to 6 points: the patient is considered healthy. 7 to 19 points: the patient is considered to be in mild depression. 20 to 34 points: the patient is considered to be in moderate depression. > 34 points: the patient is considered to be in severe depression. |
baseline | |
Primary | Simple reaction time (SRT) obtained at the MindPulse test | The "simple reaction time" (SRT) is the reaction time to the first test (the subject releases the mouse click as quickly as possible when an image appears) , it contains the time needed to perceive and analyse the image, to formulate the response and to execute the motor response. | Baseline | |
Primary | Go/NoGo score obtained at the MindPulse test | reaction time with a categorisation where the subject must react or not react (Go/NoGo) according to the categorical target, in this case a light or dark colour (white coloured image or grey coloured image). | Baseline | |
Primary | Executive speed (ES) obtained at the MindPulse test | The ES Score corresponds to the Executive Speed, i.e. the average time of categorisation of the subject. | Baseline | |
Primary | Reaction to difficulty obtained at the MindPulse test | It corresponds to the adaptation of the subject to the level of difficulty. The shift of the circle above the blue rectangle indicates a higher than expected slowing down in reaction to the difficulty of the instruction, while a shift below the blue rectangle indicates that the participant is not slowing down enough in response to the difficulty and is at risk of making mistakes. | Baseline | |
Secondary | Level of anxiety | measured by a self-questionnaire : State Trait Anxiety Inventory (STAI) 40 items rated from 1 to 4 | Baseline | |
Secondary | clinical characterisation | Measured by a scale : Transdiagnostic Skills Scale (T2S) 42 items rated from 1 to 7 | Baseline | |
Secondary | clinical characterisation | Measured by a questionnaire : Transdiagnostic Evaluation Scale (ETE) 66 items rated from 1 to 7 | Baseline | |
Secondary | insomnia severity | Measured by an insomnia severity index (ISI) 5 items rated from 0 to 4 | Baseline | |
Secondary | Stroop test | standardised cognitive assessment is measured by neuropsycological tests as stroop test | Baseline | |
Secondary | D2R | standardised cognitive assessment is measured by neuropsycological tests as D2R test that measures the concentration | Baseline | |
Secondary | Finger tapping test | standardised cognitive assessment is measured by neuropsycological tests as Finger tapping test rated from 0 to 4 | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 | |
Completed |
NCT03449979 -
Single Session of tACS in a Depressive Episode
|
N/A | |
Recruiting |
NCT05708222 -
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
|
||
Completed |
NCT01879111 -
Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback
|
N/A | |
Unknown status |
NCT01212848 -
Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation
|
Phase 3 | |
Not yet recruiting |
NCT05547711 -
Prediction and Validation of Unipolar Depression With Psychosocial-somatic Markers in a Naturalistic Cohort Recruited in an Outpatient Setting
|
N/A | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT03288714 -
Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
|
N/A | |
Completed |
NCT03899168 -
Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging
|
N/A | |
Terminated |
NCT03537547 -
Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
|
Phase 4 | |
Recruiting |
NCT05910775 -
Role Of Non-Specific Effects in The Treatment of Depression With Esketamine
|
N/A | |
Terminated |
NCT04383509 -
Electroconvulsive Treatment Followed by Cognitive Control Training
|
N/A | |
Completed |
NCT05683028 -
RCT for Electroconvulsive Treatment Followed by Cognitive Control Training
|
N/A | |
Enrolling by invitation |
NCT05701345 -
Study of Virtual Reality-based Medical Device for Patients With Depressive Disorder
|
N/A | |
Recruiting |
NCT04123301 -
Theta-Burst Stimulation in Major Depressive Episodes With Mixed Characteristics.
|
N/A | |
Completed |
NCT05686408 -
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
|
Phase 2 | |
Completed |
NCT03543410 -
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
|
Phase 2 | |
Completed |
NCT04953338 -
Mental Health Associations With Vitiligo
|
||
Recruiting |
NCT06152705 -
Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression
|
N/A |